Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for HLA-DRB4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HLA-DRB4/HLA-DRA Heterodimer ECD-Fc Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View HLA-DRB4 Products |
| Gene Delivery | HLA-DRB4 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Cell-based assays preserve native conformation. |
View HLA-DRB4 Products |
| Benchmark Ab | Anti-HLA-DR Recombinant Antibody Recombinant positive control for binding and blocking assays. |
View HLA-DRB4 Products |
| Validator | HLA-DRB4 siRNA Set For knockdown verification. |
View HLA-DRB4 Products |
| Related Target A | HLA-DRA Required heterodimerization partner for functional HLA-DR complex formation. |
View HLA-DRA Products |
| Related Target B | HLA-DRB1 Critical homology counter-screening target to ensure HLA-DRB4 specificity. |
View HLA-DRB1 Products |
| Related Target C | CD4 Co-receptor interacting with the MHC Class II complex during T-cell activation. |
View CD4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Allele-Specific Cross-Reactivity (DRB1 vs DRB4) | Recombinant HLA-DRB1/3/4/5 panel proteins strictly verified by mass spectrometry |
| Conformational Stability of Heterodimer | Co-expressed HLA-DRB4/DRA recombinant proteins with linker-stabilized folding |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live HLA-DRB4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HLA-DRB4 therapeutics is intensifying, with major players shifting focus from traditional broad immunosuppressive mAbs to allele-specific targeting and TCR-T therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting HLA-DRB4 restricted neoantigens for cancer vaccines and TCR-T cell therapies, as well as highly selective monoclonal antibodies to treat autoimmune disorders without inducing systemic immune depletion.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| TCR-T / TCR-like Abs | Adaptimmune, Immatics | Solid Tumors (Neoantigen) | Affinity Validation (Need High-Purity HLA-DRB4/DRA monomers) |
| Monoclonal Antibodies | Bristol Myers Squibb, Roche | Autoimmune Diseases | Subfamily Off-target Screening (Need HLA-DRB1/3/5 panel) |
| Lentiviral Cell Lines | Academic Institutes, Biotech | Antigen Presentation Assays | Stable Conformation (Need HLA-DRB4 Lentivirus for cell lines) |